Next Science Product Featured in Lifetime Channel Program on Treating Chronic Wounds
June 28 2021 - 5:00AM
Business Wire
“The Balancing Act” segment will highlight how
Next Science’s BLASTX® non-toxic, antimicrobial wound gel can help
heal diabetic ulcers
Next Science (ASX:NXS), an innovative medical technology company
and leader in treating biofilm-based infections in humans, today
announced new educational broadcast content about chronic
infections, which impact 17 million Americans each year. “The
Balancing Act,” a lifestyle show that airs on the Lifetime channel,
will feature a segment that discusses the costly and debilitating
nature of these infections and how physicians can more effectively
treat patients suffering from chronic wounds, including diabetic
wounds, by using BLASTX, Next Science’s antimicrobial wound
gel.
The segment shares the story of Charlie Richter, a patient who
developed a chronic foot wound that would not heal until he began
treatment with Dr. Matthew Regulski, DPM, a podiatric surgery
specialist and Next Science consultant based in New Jersey. Dr.
Regulski treated and ultimately healed the chronic wound using
BLASTX, a wound gel that breaks down biofilm, a structure that
protects bacteria and can be resistant to antibiotics.
“Taking care of patients as if they were my family is what gets
me up every day and makes me want to be the best physician I can
be,” said Dr. Regulski. “For me, it’s personal as my father was a
diabetic who had part of his foot amputated to save his life before
we had products like BLASTX. I have treated more than 20,000
patients with chronic wounds using BLASTX and it is the best tool
in my toolkit when it comes to healing diabetic ulcers and
preventing amputation – and when we save a patient’s limb we save
their life.”
Approximately 15-25% of diabetics suffer from foot ulcers and up
to 24% of those patients will require an amputation – and one of
the primary reasons is microbial infection in the biofilm
surrounding the ulcer. Microbial infections are also a leading
cause of death around the world. In the U.S., biofilm-related
infections kill an estimated 550,000 people each year – more than
chronic lower respiratory diseases, diabetes and the flu/pneumonia
combined.
“At Next Science, our purpose is to heal people and save lives
by bringing our unique technologies to healthcare professionals
around the world,” said Dustin Haines, chief commercial officer for
Next Science. “Foot ulcers pose a significant health risk to people
with diabetes. With BLASTX, physicians can feel confident they have
a superior weapon in the fight against biofilm and through
treatment that they will help improve their patients’ quality of
life.”
In addition to treating diabetic foot and leg ulcers, BLASTX can
also be used for stage I-V pressure ulcers, partial- and
full-thickness wounds, post-surgical wounds, first and second
degree burns, and grafted and donor sites. BLASTX, which uses Next
Science’s patented XBIO® Technology, which physically deconstructs
the protective shell over the bacterial biofilm matrix, destroys
bacteria within the gel and defends from recolonization while
maintaining a moist wound environment. BLASTX is non-toxic and
lasts up to five days.
The segment will air on Lifetime Television on June 28 at 7:30
a.m. EDT and will re-air on July 6 during the same time period.
To learn more about BLASTX® and download information to share
with your physician, go to www.blastxgel.com.
About Next Science
Next Science is a medical technology company headquartered in
Sydney, Australia, with a research and development center based in
Jacksonville, Florida. Established in 2012, the company’s primary
focus is on the development and continued commercialization of its
proprietary XBIO® Technology to reduce the impact of biofilm-based
infections in human health. XBIO® is a unique, non-toxic technology
with proven efficacy in eradicating both biofilm based and
free-floating bacteria. Next Science owns 100% of the patent
protected intellectual property relating to its XBIO Technology®.
For further information visit: www.nextscience.com.
About The Balancing Act
The Balancing Act® is a morning show created and produced by
BrandStar that offers sensible solutions and essential information
in a fun, entertaining format; providing resources to help people
do life better. The Balancing Act features everything from
delicious recipes, style makeovers and dream getaways to parenting
tips and the latest news in health and wealth. Tune in to The
Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime®, and find
all previously aired episodes on TheBalancingAct.com.
About BrandStar
We’re matchmakers; connecting People to Brands to Do Life
Better. BrandStar has unparalleled experience in creating
customized educational content for brands with laser targeted
extensive distribution through their multi-channel network
ecosystem and methodology. From Original television programming on
Lifetime, BrandStar.tv, social media, digital marketing, to media
management and PR; BrandStar helps brands connect with the right
consumer, at the right time, with the right message, through all
the right channels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210628005066/en/
Anthony Priwer Dalton Agency (615) 515-4891
apriwer@daltonagency.com
Next Science (ASX:NXS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Next Science (ASX:NXS)
Historical Stock Chart
From Dec 2023 to Dec 2024